This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix initiates travoprost implant trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been treated in a proof-of-concept clinical trial of a travoprost implant under study for the treatment of glaucoma, Ocular Therapeutix announced in a press release.

The travoprost product, OTX-TIC, is bioresorbable, delivered via intracameral injection and intended to reduce IOP in patients with glaucoma or ocular hypertension.

The phase 1 prospective, open-label, multicenter study is being conducted in the U.S. Safety, efficacy, durability and tolerability will be assessed.

The target duration of drug delivery for one sustained-release dose of OTX-TIC into the anterior chamber of the eye is 4 to 6 months, according to the release.

“OTX-TIC is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant,” Michael Goldstein, MD, chief medical officer of Ocular Therapeutix, said in the release.